On August 31, 2026 TriSalus Life Sciences Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, reported that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference. Management will participate in one-on-one meetings on Monday, September 14 and Tuesday, September 15, and will participate in a Fireside chat on Monday, September 14 at 5:00 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast replay of the Fireside chat will be available for 90 days following the Fireside chat in the Events section of the TriSalus Investor website at www.investors.trisaluslifesci.com.

(Press release, TriSalus Life Sciences, AUG 31, 2026, View Source [SID1234670467])